moiety and the second antigen-binding moiety mentioned are fused, wherein the first antigen-binding moiety and the second antigen-binding moiety target different epitopes of different antigens, respectively. The first antigen-binding moiety and the second antigen-binding moiety mentioned are fused, wherein they may be directly linked (e.g., directly linked by the terminal amino acids of the two), may be indirectly linked by a linker, or may have additional functional region sequences, such as an Fc region, a CH1, and a CL sequence, linked between them. It should be noted that the terms "first", "second", and "third" as used herein, are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly indicating the number of indicated technical features, nor should they be used to indicate an order of appearance. The terms "first antigen-binding moiety", "second antigen-binding moiety", and "third antigen-binding moiety" mean moieties capable of binding to different epitopes of different target antigens or different epitopes of the same target antigen, which may be intact antibodies or part of an intact antibody, such as heavy chain variable regions, Fab, Fab', F(ab')2, single-chain antibodies (ScFvs), or single-domain antibodies (sdAbs). According to a preferred embodiment of the present disclosure, the "first antigen-binding moiety", the "second antigenLIbinding moiety", and the "third antigen-binding moiety" specifically bind to different epitopes of different antigens, respectively.

[0120] Herein, "linker" and "linking fragment" have the same meaning. Linkers may be some oligopeptides or polypeptides, and may be any amino acid sequences capable of providing flexibility. Useful linkers are those commonly used in the art, including, but not limited to, the group consisting of: GS, SG, GGS, GSG, SGG, GGG, GGGS (SEQ ID NO. 62), SGGG (SEQ ID NO. 63), GGGGS (SEQ ID NO. 64), GGGGGSGS (SEQ ID NO. 65), GGGGSGS (SEQ ID NO. 66), GGGGSGGS (SEQ ID NO. 70), GGGGSGGGGSGGGGS (SEQ ID NO. 18), GGGGSGGGGS (SEQ ID NO. 61), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO. 67), GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO. 68), GGGGSGGGGSGGGGSGGGGSGGGGSGGGS (SEQ ID NO. 69), etc.

[0121] The first antigen-binding moiety provided is capable of specifically recognizing and binding to the extracellular antigen determining region of the labeling polypeptide. According to a specific embodiment, the first antigen-binding moiety provided is capable of specifically recognizing and binding to the amino acid sequence set forth in SEQ ID NO: 1, 2, 3, 4, or 5 mentioned above. According to a specific embodiment, the first antigen-binding moiety provided comprises one or more